Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

No authors listed

Published Erratum

No authors listed. Immunother Adv. 2023.

. 2023 Oct 12;3(1):ltad018.

doi: 10.1093/immadv/ltad018. eCollection 2023.

Abstract

[This corrects the article DOI: 10.1093/immadv/ltac021.].

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Barth S, Naran K. Barth S, et al. Immunother Adv. 2022 Oct 21;2(1):ltac021. doi: 10.1093/immadv/ltac021. eCollection 2022. Immunother Adv. 2022. PMID: 36406467 Free PMC article.

Correction.
[No authors listed] [No authors listed] Immunother Adv. 2022 Aug 11;2(1):ltac018. doi: 10.1093/immadv/ltac018. eCollection 2022. Immunother Adv. 2022. PMID: 35967910 Free PMC article.
Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
[No authors listed] [No authors listed] Immunother Adv. 2023 Feb 18;3(1):ltad002. doi: 10.1093/immadv/ltad002. eCollection 2023. Immunother Adv. 2023. PMID: 36819977 Free PMC article.
Correction to: Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity.
[No authors listed] [No authors listed] Immunother Adv. 2023 Jul 27;3(1):ltad004. doi: 10.1093/immadv/ltad004. eCollection 2023. Immunother Adv. 2023. PMID: 37521948 Free PMC article.
Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
Bailly C, Thuru X, Quesnel B. Bailly C, et al. Cancers (Basel). 2021 Dec 18;13(24):6365. doi: 10.3390/cancers13246365. Cancers (Basel). 2021. PMID: 34944985 Free PMC article. Review.
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
Gomes de Morais AL, Cerdá S, de Miguel M. Gomes de Morais AL, et al. Curr Oncol Rep. 2022 May;24(5):651-658. doi: 10.1007/s11912-022-01218-y. Epub 2022 Feb 26. Curr Oncol Rep. 2022. PMID: 35218498 Review.